Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Oncology Venture provides further information on the terms for a proposed rights issue

Regulatory

Oncology Venture appoints new CEO and CFO and proposes rights issue to facilitate a focused commercial strategy

Regulatory

Oncology Venture publishes Interim Report for the period January – June 2019

Regulatory

FDA grants IDE approval to use Oncology Venture’s LiPlaCis DRP for patient selection in a pivotal Phase 3 study

Regulatory

Oncology Venture – First day of trading in investor warrants

Regulatory

New company takes over Certified Advisor role to OV

Regulatory

Oncology Venture gets European patent on its AI powered method to find patients who will benefit from LiPlaCis

Regulatory

Oncology Venture provides financial details regarding its recent acquisition of additional ownership in dovitinib

Regulatory

Oncology Venture increases its ownership in dovitinib

Non-Regulatory

OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

Regulatory

Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis

Regulatory

Oncology Venture publishes Q1 report for 2019

Regulatory

Oncology Venture – New date for registration of current rights issue

Regulatory

Oncology Venture has successfully executed capital increase with a value in excess of SEK 80m.

Regulatory

Oncology Venture management participates in current rights issue

Regulatory

Oncology Venture prolongs subscription period

Regulatory

Oncology Venture provides news on its clinical development projects dovitinib, 2X‑121 and LiPlaCis

Non-Regulatory

Oncology Venture Investor Events in Q2 2019 – new event

Non-Regulatory

Oncology Venture Investor Events in Q2 2019

Non-Regulatory

Editorial in Pharmagenomics explains how DRP® can guide the treatment for breast cancer